Saudi housing minister hands over new Riyadh units to tenants in Sakani program

Housing Minister Majid Al-Hogail, second right, handed over housing units to beneficiaries of the Sakani program. (SPA)
Short Url
Updated 26 January 2020

Saudi housing minister hands over new Riyadh units to tenants in Sakani program

  • Diyar Al-Saad housing project occupies ​133,000 square meters in Al-Jawan in northern Riyadh

RIYADH: Housing Minister Majid Al-Hogail on Saturday handed over housing units to beneficiaries of the Sakani program, as part of the first phase of the Diyar Al-Saad housing project in the residential suburb of Al-Jawan in northern Riyadh.

Diyar Al-Saad is a Housing Ministry project implemented in partnership with the private sector, and can accommodate more than 100,000 people. It is providing nearly 600 housing units, including villas and townhouses.

Al-Hogail toured the project and inspected completion rates. He stressed the need to speedily complete the remaining stages so as to meet deadlines in preparation to hand units over to beneficiaries.

Diyar Al-Saad occupies ​133,000 square meters and includes educational, health, commercial and recreational services sites, in addition to parks.

Infrastructure for water, electricity, telecommunications, sewage and rain drainage has been completed.

Diyar Al-Saad is one of 16 projects providing a total of 30,000 housing units in Riyadh at prices ranging from SR250,000 ($66,639) to SR750,000. 


Major Saudi research center prepares to take part in advanced COVID-19 vaccine trials

Updated 22 September 2020

Major Saudi research center prepares to take part in advanced COVID-19 vaccine trials

  • Ministry of Health and King Abdullah International Medical Research Center have been working with two Chinese drug companies

JEDDAH: King Abdullah International Medical Research Center (KAIMRC) in Saudi Arabia is preparing to take part in advanced trials of one or two COVID-19 vaccines.

About 40 potential vaccines are being tested on humans, nine of which are at the advanced stage of clinical trials to evaluate their safety and effectiveness in protecting people against a virus that has infected more than 31 million people around the world.

The center confirmed its readiness to cooperate with the Kingdom’s Ministry of Health and the Saudi Food and Drug Authority (SFDA) and participate in tests of one or two of the nine vaccines that are in the third phase of clinical trials, during which large-scale testing on humans takes place.

Dr. Naif Al-Harbi, the head of KAIMRC’s drug-development unit, told Al-Ekhbariya TV news channel that it is unprecedented to have nine vaccines in stage three of clinical trials so soon, less than a year, after the emergence of a new virus.

“Approval or disapproval of any drug normally follows the third stage of its clinical trials, which is the last stage,” he added. “Since the pandemic, KAIMRC has been in continuous contact with a number of drug companies in four countries (that are developing vaccines).”

KAIMRC has been working with one Chinese pharmaceutical company in particular to help evaluate and accelerate the development of its vaccine, he said.

“Over the past two months, we have been in contact with Sinovac to scientifically evaluate its product, in term of the tests on animals and a study of the results of stages one and two on humans,” Al-Harbi said.